This study extends earlier findings of the authors demonstrating that meloxicam, a selective inhibitor of cyclooxygenase 2, supports hematopoietic recovery in sublethally irradiated mice and is radioprotective when given before irradiation. We report here that when meloxicam was administered in a single dose 1 h after a lethal 9-Gy whole-body dose, an increased 30-day survival was achieved. Additional studies showed that administration of meloxicam 24 h after lethal irradiation is ineffective and its repeated administration deleterious. Possible mechanisms of the therapeutic effects of meloxicam administered early after irradiation are discussed.

Laboratory of Experimental Hematology Institute of Biophysics v v i Academy of Sciences of the Czech Republic Královopolská 135 CZ 61265 Brno Czech Republic

References provided by Crossref.org

Brief Story on Prostaglandins, Inhibitors of their Synthesis, Hematopoiesis, and Acute Radiation Syndrome

Impaired post-irradiation survival of cyclooxygenase-2-deficient mice

Hematological profile of untreated or ionizing radiation-exposed cyclooxygenase-2-deficient mice

Pharmacological Modulation of Radiation Damage. Does It Exist a Chance for Other Substances than Hematopoietic Growth Factors and Cytokines?

Granulocyte colony-stimulating factor in the treatment of acute radiation syndrome: a concise review

Agonist of the adenosine A3 receptor, IB-MECA, and inhibitor of cyclooxygenase-2, meloxicam, given alone or in a combination early after total body irradiation enhance survival of γ-irradiated mice

Stimulatory action of cyclooxygenase inhibitors on hematopoiesis: a review